Ingredients by Nature has announced the publication of its research investigating Eriomin, its patented citrus flavonoid blend, on prediabetic microbiota. The research published in the Food Science & Nutrition Journal demonstrated that Eriomin could attenuate intestinal dysbiosis.
The 12-week double-blind, randomised controlled clinical trial included male and female volunteers with prediabetes ages 30-69 years old. Study participants were given 200 mg/day of Eriomin or a placebo and instructed to maintain their usual diet. Two registered dietitians followed study participants during the trial period, and blood and fecal samples were collected at the beginning and end of the study.
After 12 weeks of Eriomin supplementation, researchers found reduced growth of Firmicutes – main microbiota phylum, typically found in high levels in prediabetic and obese individuals and associated with a carbohydrate-rich diet.
Eriomin also decreased the abundance of the Lachnospiraceae family, which is linked to glycemic dysregulation, metabolic syndrome, excess weight and prediabetes. In contrast, the Ruminococcaceae family increased by 38% with Eriomin, while it decreased with placebo. These microorganisms produce short-chain fatty acids that can strengthen the intestinal barrier and support a healthy inflammatory response.
This is the third published human clinical trial backing Eriomin. We are thrilled to share this news with the industry and will continue investigating Eriomin’s powerful effects
- Rob Brewster, President of Ingredients by Nature
There has also been a decrease in the genus Blautia, which has been linked to the weakening of the intestinal walls (Lambeth et al., 2015). Furthermore, a positive correlation was found between Blautia and hyperglycemia, suggesting that Blautia depletion was associated with reduced blood glucose in patients treated with Eriomin.
Of additional importance, Eriomin decreased volunteers’ fasting blood glucose by 6.5% and increased GLP-1 incretin by 22%; both results were statistically different from the placebo group (p<0.05).
“These results further demonstrate Eriomin’s potential for those who need support in maintaining healthy blood glucose levels,” said Rob Brewster, President of Ingredients by Nature. “This is the third published human clinical trial backing Eriomin. We are thrilled to share this news with the industry and will continue investigating Eriomin’s powerful effects for numerous health benefits.”
Eriomin is a high-potency proprietary lemon flavonoid blend primarily composed of Eriocitrin, a flavonoid naturally found in lemons and oranges. Eriomin is clinically validated to aid in maintaining healthy blood glucose levels, support normal insulin sensitivity, increase glucagon-like peptide -1 (GLP-1), manage inflammation, and reduce oxidative stress and now, support a healthy microbiota.
